Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-65
SponsorKonkuk University Medical Center
About this trial
The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.
Eligibility criteria
Qualifiers
patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent
Disqualifiers
preoperative renal failure requiring reran replacement therapy
preoperative liver disease
preoperative low cardiac output (EF < 50%)
Preoperative IABP application, Atrial fibrillation, Pacemaker
Trial design
Treatments tested in this trial
- Acute normovolemic hemodilution (ANH)
- hydroxyethyl starch (HES 130/0.6)
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov